TW518236B - Finely divided, substantially crystalline particles of budesonide, pharmaceutical composition comprising them and the preparation thereof - Google Patents
Finely divided, substantially crystalline particles of budesonide, pharmaceutical composition comprising them and the preparation thereof Download PDFInfo
- Publication number
- TW518236B TW518236B TW087107532A TW87107532A TW518236B TW 518236 B TW518236 B TW 518236B TW 087107532 A TW087107532 A TW 087107532A TW 87107532 A TW87107532 A TW 87107532A TW 518236 B TW518236 B TW 518236B
- Authority
- TW
- Taiwan
- Prior art keywords
- patent application
- finely divided
- item
- scope
- particles according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
五 、發明説明( A-7 B7 經濟部中夾標準局貞工消费合作社印製 /發明提Γ 了地去聽的細碎顆粒及其製備法。本發明 粒於治療和製造用於治療呼吸上::物、使用該顆 原呼及系統涡變的藥物,以及治療 的的方法,通過將該顆粒投藥給需要這一治療顆碎的顆粒經吸入投藥用於治療,希望藥物 二木透入師。廷些細碎的藥物顆粒通常由諸如降低微 ^和研磨等技術製造。也可應用很多其他製造技術。 技術,特定言之降低微粒·體積技術,可產生具有部 操疋形結構區域和不規則形狀的顆粒,但就醫藥用途而 通书疋足純足的。然而,當保存於不利環境時,這些 粒易於改變其結構,諸如通常當儲存藥物時(如在高濕 下’能導致聚集),和/或當患者正在使用者。過去, 顆粒經受諸如在世界專利95/〇58〇5中公佈的調節過程,U 克服無定形區域的問題,但顆粒的形狀不規則問題仍然存 在。顆粒形狀是重要的,因爲任何不規則性會增加顆粒黏 在一起的傾向。因而難以在肺内分散。已找到這些問題 解法。 按照本發明,問題已解決,通過提供細碎的、實際上 晶體顆粒的丁地去炎松,其特#爲顆粒大體上光滑,並 有表面積BET氣體吸收數値從1,以從2.0較佳,至4.5, 至3.6米2/克較佳。 本發明充分確定的小顆粒爲用於吸入的有效調配之先次 (r'件如可通過藥物投配量進入肺的那邵份增加而觀察到 請 先 閲 讀 背 之 注 意 事 •項 再 填 寫 本 頁 衊 份言 顆度使 已 訂 的 具 以 決 -----_~ 4 - 本紙張尺度適用中國國家標準(CNS ) Μ規格(21QX 297公楚)
五、 發明説明( M濟部中央標準局工消費合作社印製 點。較之較高表面積的晶體(如不規則晶體),低表面 知的晶體黏在一起的傾向較低。 表面知用BET氣體及贩測足,如用F1GWSMb Η 2綱或美 Micromeritics Co·的Gemini 23 70測定,敘述於國際標準 化組織/技術通報24SC4N55(第7稿)及其中的參考文獻内。 本發明的顆粒之光滑度由圖丨説明,這是本發明的顆粒之 掃描電子顯微照片(SEM),使請〇L掃描顯微鏡⑽ 5 2 0 〇拍攝。 化按照本發明的細碎顆粒的總尊中位直徑(mmd)以小於ι〇 微米爲佳,小於5微米較佳,小於3微米更佳。 =照本發明的顆粒具有實際上是晶體的形式,以至少95 重量%結晶度較佳’其中實際上沒有無定形區域。本發明的 幸l、..D印度由圖2 X _射線衍射圖形所説明。本發明的顆 =再結晶能量以小於U焦爾/克較佳,以小於〇 5焦爾 更佳,使用Therm〇 Metric 227熱活性檢測器測定。 知顆粒樣品暴露於25。(:溫度和94%相對濕度24小時,並記 錄樣品散熱量,以進行測定。 2過將落劑中的丁地去炎松溶液與超臨界液體共同幻入 备,调fe儀器的溫度和壓力,致使經超臨界液體的作用 ’ ^的分散和萃取實際上同,發生,由此可製備本發明 ^砰的顆粒。活性物質丁地去炎松從而直接沉殿進入且 :斤而物理·化學性質的可適用於呼吸系統的小顆粒。通常 仿其臨界=力和臨界溫度時(或高於兩者時),超臨界液體 乂 存在’·以二氧化碳較佳。用於溶解丁地去炎 本紙張尺度適用中國 ;—— (請先閲讀背面之注意事碩苒填寫本頁)
、1T ml 1 - 0 -j I — -1 •ϋ^ I - 5 - 518236 經濟部中央標準局負工消f合作社印製 ΑΊ 五、發明説明(3 ) ^-- 松的溶劑以有機溶劑較佳,如丙酮或甲醇。方法以使用在 世界專利9:)/01221中公佈的儀器來進行較佳。 按知、本發明的細碎的顆粒以用於治療呼吸系統病键(士 哮喘)較佳。本發明進一步提供醫藥組合物,包括按照本 發明的細碎的顆粒和醫藥上可接受的載體或稀釋劑,如乳 糖。本發明也&供使用按照本發明的細碎的顆粒製造用於 治療呼吸系統病變的藥物。 、 按照本發明的細碎的顆粒可用於種種醫藥調配物,如生 產片劑,或裝入膠囊供口服使用。然而,細碎的顆粒以用 於生產吸入調配物較佳。按照本發明的細碎的顆粒因而可 自身單獨使用,或與賦形劑(如乳糖)混合使用,賦形劑的 J大]大万;藥物的,或與其大致相同。這類粉劑調配物 可用於膠囊,如用於Spinhaler⑧,或用於其他吸入器, 如 Turbuhaler⑧、Rotahaler®、⑧或 。按照本發明的細碎的顆粒可使㊉已知技術進一步處理, 如團成球狀,以提供軟藥丸,或軟顆粒,其強度足以可使 其裝^容器而不致崩解,但當吸入投藥時,弱得足以分解 成細碎的組成顆粒。 本發明由以下實例來説明,但這不應解釋爲本發明受此 限制。 實例1 ▲備5有1 . 0 % (重! /體積)丁地去炎松的丙酮溶液,使 :〇.\5微米注口,向在世界專利95/01221中所述的儀器進 'H毛升/分知)。超臨界二氧化碳的流量爲〇毫升/ (請先閲讀背面之注-意事項再填寫本頁;>
518236 A-7 B7 五、發明説明( 分鐘。工作條件爲100巴和60。〇。以88%得率得到丁地去炎 松的光滑、白色結晶細粉,BET數値爲36米2〆克(使用 Gemini 2j75 V1.01測足),顆粒大小爲2 25微米(MMD) 。細碎的S Ε Μ·顯示於圖1中。 . 實例2 製備含有2.5 %(重量/體積)丁地去炎松的丙酮溶液,向 在實例1中所用的同樣儀器進料(0·2毫升/分鐘)。超臨界 一氧化竣的流量爲9.0耄升/分鐘。工作條件爲丨〇 〇巴和8 〇 C。得到丁地去炎松的光滑、白色結晶細粉,其χ _射線衍 射圖形顯示於圖2中。 貫例3 製備含有1 . 0 % (重量/體積)丁地去炎松的丙酮溶液,使 用〇.^5微米注口,向在世界專利95/〇1221中所述的儀器進 料(1.5毫升/分鐘)。超臨界二氧化碳的流量爲45毫升/分 鐘。工作條件爲100巴和60。〇。以82%得率得到丁地去炎松 的光滑、白色結晶細粉,ΒΕΤ數値爲2〇米2/克(使用
Gemini 2375 V1.01測足),顆粒大小爲4 62微米(MMD)。 實例4 經濟部中夾標隼局g〈工消费合作社印製 - , II- _ y -i y 1*· --- - -- - I (請先閲讀背面之注意事項.再填寫本頁) 製備含有2.5 %(重量/體積)丁地去炎松的丙酮溶液,使 用〇·3)微米注口,向在世界專苎95/01221中所述的儀器進 料U.5愛升/分鐘)。超臨界二氧化碳的流量爲45毫升/分 叙。工作條件爲1 0 0巴和8 0 °C。以8 3 %得率得到丁地去炎松 的光滑、白色結晶細粉,B E T數値爲2.5米2 /克(使用
Gemini 2375 V 1.01測定),顆粒大小爲3 3 3微米(Μ μ D)。
Claims (1)
- 518236 第〇87107532號專利申請案 ^ 中文申請專利範圍修正本(91年7月) ^、申請專利範圍 :―— ,1' -|*广 1 . 一種丁地去炎松(budesonide)之細碎的實質晶體顆粒, 其特徵為顆粒大體上光滑,BET數值從1至4.5米2/ 克。 2 ·根據申凊專利範圍第1項之細碎顆粒,其特徵為具有2 . 〇 至3.6米2/克的BET數值。 3·根據申請專利範圍第1或2項之細碎顆粒,其特徵為具有 小於1焦耳/克的再結晶能。 4 ·根據申請專利範圍第丨或2項之細碎顆粒,其特徵為具有 小於1 0微米的總體中位直徑。 5 ·根據申請專利範圍第丨或2項之細碎顆粒,其係用於治療 呼吸系統疾患。 … 6 · —種用於治療呼吸系統病變之醫藥組合物,其包含根據 申凊專利範圍第1或2項之細碎顆粒和醫藥上可接受的載 體或稀釋劑。 7 ·根據申請專利範圍第!或2項之細碎顆粒,其係用於製造 用於治療呼吸系統病變的藥物。 種用於/σ療呼吸系統病變之醫藥組合物,其包括有效 劑量之根據申請專利範圍第1或2項之細碎顆粒。 9· 一種製備根據申請專利範圍第丨或2項之細碎顆粒之方法 ,其特徵為有機溶劑中的丁地去炎松 與超臨界二氧化碳共同引入儀器,其中溫度係於60 °C至 80 C且壓力是於95巴至15〇巴,致使經超臨界二氧化碳的 作用,有機溶劑的分散和萃取實際上同時發生。 ΐ纸張尺度適財a a家襟準(⑽)規格(⑽χ挪公董)-:---
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9701956A SE9701956D0 (sv) | 1997-05-23 | 1997-05-23 | New composition of matter |
Publications (1)
Publication Number | Publication Date |
---|---|
TW518236B true TW518236B (en) | 2003-01-21 |
Family
ID=20407079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW087107532A TW518236B (en) | 1997-05-23 | 1998-05-15 | Finely divided, substantially crystalline particles of budesonide, pharmaceutical composition comprising them and the preparation thereof |
Country Status (28)
Country | Link |
---|---|
US (2) | US6346523B1 (zh) |
EP (1) | EP1005328B1 (zh) |
JP (1) | JP2001525850A (zh) |
KR (1) | KR100514971B1 (zh) |
CN (1) | CN1146406C (zh) |
AR (1) | AR015820A1 (zh) |
AT (1) | ATE246492T1 (zh) |
AU (1) | AU734763B2 (zh) |
BR (1) | BR9808812A (zh) |
CA (1) | CA2290538C (zh) |
DE (1) | DE69816997T2 (zh) |
DK (1) | DK1005328T3 (zh) |
EE (1) | EE03850B1 (zh) |
ES (1) | ES2205496T3 (zh) |
HU (1) | HUP0002212A3 (zh) |
ID (1) | ID24332A (zh) |
IL (1) | IL133098A (zh) |
IS (1) | IS5254A (zh) |
NO (1) | NO995540L (zh) |
NZ (1) | NZ500852A (zh) |
PL (1) | PL336902A1 (zh) |
PT (1) | PT1005328E (zh) |
SE (1) | SE9701956D0 (zh) |
SK (1) | SK158799A3 (zh) |
TR (1) | TR199902880T2 (zh) |
TW (1) | TW518236B (zh) |
WO (1) | WO1998052544A1 (zh) |
ZA (1) | ZA984127B (zh) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0810853B1 (en) * | 1995-02-24 | 2004-08-25 | Elan Pharma International Limited | Aerosols containing nanoparticle dispersions |
CN1192810C (zh) | 2000-03-03 | 2005-03-16 | 贝林格尔·英格海姆药物公司 | 通过反复的溶剂膨胀-收缩处理物料 |
EP1354581A4 (en) * | 2000-12-26 | 2007-07-04 | Takeda Pharmaceutical | POROUS SUBSTANCE AND METHOD FOR THE PRODUCTION THEREOF |
GB0106403D0 (en) * | 2001-03-15 | 2001-05-02 | Pharmaceutical Profiles | Labelling of dry powder formulations for inhalation |
GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
CA2456806C (en) | 2001-08-08 | 2011-10-18 | Brown University Research Foundation | Methods for micronization of hydrophobic drugs |
DK1435916T3 (da) * | 2001-10-10 | 2006-08-21 | Boehringer Ingelheim Pharma | Pulverbearbejdning med tryksatte gasformige fluider |
US20030129242A1 (en) * | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
GB0216562D0 (en) * | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
CA2523035C (en) | 2003-05-22 | 2011-04-26 | Elan Pharma International Ltd. | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
US20070020196A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
EP1730751B1 (en) * | 2004-03-12 | 2009-10-21 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | A magnetoresistive medium |
US20090186088A1 (en) * | 2005-03-18 | 2009-07-23 | Nanomaterials Technology Pte Ltd | Inhalable drug |
EP1904219A4 (en) | 2005-07-15 | 2011-07-27 | Map Pharmaceuticals Inc | METHOD FOR FORMING PARTICLES |
EP1782839A1 (en) | 2005-11-03 | 2007-05-09 | Genetic S.p.A. | Sterilization process of Glucocorticosteroid by supercritical CO2 |
US20070185066A1 (en) * | 2005-12-20 | 2007-08-09 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070160542A1 (en) * | 2005-12-20 | 2007-07-12 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070178049A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
US20070249572A1 (en) * | 2005-12-20 | 2007-10-25 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
US20070197486A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids |
US20070178051A1 (en) * | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
JP2009526860A (ja) * | 2006-02-15 | 2009-07-23 | ティカ レーケメデル アーベー | 安定したコルチコステロイド混合物 |
US8148377B2 (en) | 2007-02-11 | 2012-04-03 | Map Pharmaceuticals, Inc. | Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile |
US20100294986A1 (en) * | 2009-05-19 | 2010-11-25 | Massachusetts Institute Of Technology | Supercritical fluid facilitated particle formation in microfluidic systems |
US20100298602A1 (en) * | 2009-05-19 | 2010-11-25 | Massachusetts Institute Of Technology | Systems and methods for microfluidic crystallization |
CA2812263A1 (en) * | 2010-09-22 | 2012-03-29 | Map Pharmaceuticals, Inc. | Corticosteroid particles and method of production |
CN102975731B (zh) * | 2012-04-24 | 2015-08-12 | 南车南京浦镇车辆有限公司 | 轨道车辆司机室骨架与车体的安装结构 |
WO2021219230A1 (en) | 2020-04-30 | 2021-11-04 | Paolo Fiorina | Antiviral treatment |
KR102567655B1 (ko) | 2020-11-13 | 2023-08-17 | 주식회사 비츠로이엠 | 진공커패시터 및 진공커패시터 제조 방법 |
KR20230072023A (ko) | 2021-11-17 | 2023-05-24 | 주식회사 비츠로이엠 | 가변형 진공 커패시터의 나선형 전극 위치 결정구조 |
KR20230072022A (ko) | 2021-11-17 | 2023-05-24 | 주식회사 비츠로이엠 | 가변형 진공 커패시터 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1282405C (en) | 1984-05-21 | 1991-04-02 | Michael R. Violante | Method for making uniformly sized particles from water-insoluble organic compounds |
AU624421B2 (en) | 1988-10-05 | 1992-06-11 | Pharmacia & Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
GB9001635D0 (en) | 1990-01-24 | 1990-03-21 | Ganderton David | Aerosol carriers |
DE69112917T2 (de) | 1990-06-15 | 1996-05-15 | Merck & Co Inc | Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse. |
SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
ATE213946T1 (de) * | 1991-12-18 | 2002-03-15 | Formoterol und budesonide enthaltende zusammensetzung | |
GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
-
1997
- 1997-05-23 SE SE9701956A patent/SE9701956D0/xx unknown
-
1998
- 1998-05-15 ES ES98924697T patent/ES2205496T3/es not_active Expired - Lifetime
- 1998-05-15 CA CA002290538A patent/CA2290538C/en not_active Expired - Fee Related
- 1998-05-15 ID IDW991396A patent/ID24332A/id unknown
- 1998-05-15 US US09/091,453 patent/US6346523B1/en not_active Expired - Fee Related
- 1998-05-15 AU AU76800/98A patent/AU734763B2/en not_active Ceased
- 1998-05-15 BR BR9808812-2A patent/BR9808812A/pt not_active Application Discontinuation
- 1998-05-15 SK SK1587-99A patent/SK158799A3/sk unknown
- 1998-05-15 DK DK98924697T patent/DK1005328T3/da active
- 1998-05-15 EP EP98924697A patent/EP1005328B1/en not_active Expired - Lifetime
- 1998-05-15 ZA ZA984127A patent/ZA984127B/xx unknown
- 1998-05-15 WO PCT/SE1998/000908 patent/WO1998052544A1/en active IP Right Grant
- 1998-05-15 CN CNB988053381A patent/CN1146406C/zh not_active Expired - Fee Related
- 1998-05-15 NZ NZ500852A patent/NZ500852A/en unknown
- 1998-05-15 TW TW087107532A patent/TW518236B/zh not_active IP Right Cessation
- 1998-05-15 PT PT98924697T patent/PT1005328E/pt unknown
- 1998-05-15 HU HU0002212A patent/HUP0002212A3/hu unknown
- 1998-05-15 IL IL13309898A patent/IL133098A/xx not_active IP Right Cessation
- 1998-05-15 JP JP55028498A patent/JP2001525850A/ja not_active Ceased
- 1998-05-15 KR KR10-1999-7010785A patent/KR100514971B1/ko not_active IP Right Cessation
- 1998-05-15 TR TR1999/02880T patent/TR199902880T2/xx unknown
- 1998-05-15 EE EEP199900533A patent/EE03850B1/xx not_active IP Right Cessation
- 1998-05-15 PL PL98336902A patent/PL336902A1/xx unknown
- 1998-05-15 AT AT98924697T patent/ATE246492T1/de not_active IP Right Cessation
- 1998-05-15 DE DE69816997T patent/DE69816997T2/de not_active Expired - Lifetime
- 1998-05-22 AR ARP980102400A patent/AR015820A1/es not_active Application Discontinuation
-
1999
- 1999-11-12 NO NO19995540A patent/NO995540L/no not_active Application Discontinuation
- 1999-11-18 IS IS5254A patent/IS5254A/is unknown
-
2001
- 2001-11-06 US US09/992,940 patent/US6468994B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW518236B (en) | Finely divided, substantially crystalline particles of budesonide, pharmaceutical composition comprising them and the preparation thereof | |
TW475904B (en) | Pharmaceutical composition for administration by inhalation and the preparation thereof | |
TW557217B (en) | Pharmaceutical dry powder compositions for use in treating respiratory disorders and the process for preparing the same | |
TW492877B (en) | Process for the preparation of respirable particles | |
JP4792457B2 (ja) | 高度に呼吸に適したインスリンのマイクロ粒子 | |
EP3618811B1 (en) | A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery | |
JPH05507935A (ja) | エアゾール医薬製剤 | |
WO1999027911A1 (fr) | Medicament en pastilles souples et procede de fabrication | |
JP2004510731A (ja) | 2つ以上の活性成分の組合せを組み込んだ吸入粒子 | |
JP2010059179A (ja) | ブデソニドを含む0.28から0.38g/MLのかさ密度を有する吸入用新規製剤 | |
WO2021203914A1 (zh) | 一种帕拉米韦干粉吸入剂及其制备方法 | |
KR20190027844A (ko) | 흡입용 의약 조성물 | |
TW200304376A (en) | Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof | |
CN112137957B (zh) | 一种药用吸入气雾剂及其制备方法 | |
MXPA99010584A (en) | Composition comprising finely divided, crystalline particles of budesonide | |
JP4512202B6 (ja) | ブデソニドを含む0.28から0.38g/MLのかさ密度を有する吸入用新規製剤 | |
CZ414899A3 (cs) | Kompozice obsahující jemně rozptýlené, krystalické částice budesonidu | |
de Castroa et al. | Development of inhaled formulation of modified clofazimine as an 2 alternative to treatment of tuberculosis | |
MXPA00005270A (en) | Soft-pellet drug and process for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |